SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : UK AND EUROPEAN BIOTECHS.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: James Silverman who wrote (8)12/17/1996 1:39:00 PM
From: James Reynolds   of 64
 
James,

British Biotech shares made huge gains on the back of marimastat,its oral MMP inhibitor for cancer, which showed impressive results in Phase II trials. Chiroscience is working on a second generation oral MMP inhibitor for cancer which should enter Phase I by mid 97. It is hoped tht it will be more selective and show fewer side effects than
British Biotech's drug.

Chiroscience's MMP inhibitor for rheumatoid and osteo arthritis is taken orally. Although it is early days and efficacy will not be proven until Phase II trials, a successful drug to treat these conditions would have "blockbuster" potential.

Apart from MMP inhibitors for arthritis and cancer, the Company is also working on MMP compounds for inflammatory disorders (such as inflammatory bowel disorder), skin disorders and cardiovascular conditions atherosclerosis and congestive heart failure.

The recent acquisition of Darwin further enhances Chiroscience's all round drug discovery capabilities, particularly in other areas such as gene therapy.

Regards,

James
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News